A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
NCT ID: NCT00417937
Last Updated: 2023-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
98 participants
INTERVENTIONAL
2007-01-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel
NCT03094403
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
NCT01257919
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
NCT00617903
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
NCT01025635
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
NCT01555463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Azelaic acid 15 % gel once daily
azelaic acid 15% gel
15% gel, topically applied once daily for six weeks
2
Azelaic acid 15 gel twice daily
azelaic acid 15% gel
15% gel, topically applied twice daily for six weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
azelaic acid 15% gel
15% gel, topically applied once daily for six weeks
azelaic acid 15% gel
15% gel, topically applied twice daily for six weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Rosacea with marked ocular manifestations
* Presence of dermatoses that could interfere with the rosacea diagnosis or evaluation of the study course
* Wash out period required for patients treated prior to study with topical retinoids, oral antibiotics, topical antibiotics, systemic and topical corticosteroids, topical imidazole, laser surgery for telangiectasia
* History of hypersensitivity to propylene glycol
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intendis GmbH
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1401460
Identifier Type: OTHER
Identifier Source: secondary_id
14428
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.